FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Mylan to Pay $465 Million Settlement for Classifying EpiPens as Generics

Aug. 30, 2017
A A

Mylan agreed to pay $465 million in a False Claims Act settlement over the classification of its EpiPen as a generic.

The Justice Department claimed the company classified the EpiPen as a generic to avoid paying rebates it owed to Medicaid. Using the classification, Mylan was able to hike EpiPen prices 400 percent between 2010 and 2016 while paying a fixed 13 percent rebate to Medicaid.

Sanofi, the initial whistleblower in the case, will receive approximately $38.7 million from the settlement.

View today's stories